LENZ Therapeutics Inc. Common Stock (LENZ)
Stock · NASDAQ · Health Care
$3.28as of 10/16/2026
Price chart
Active signals
LENZ Signal Track Record
How signals performed across all stocks →What LENZ's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | -1.9% | 44% | September 2, 2026 |
| Bollinger Band Breakout | 24 | -0.3% | 50% | September 2, 2026 |
| Bollinger Band BreakdownActive now | 18 | +3.8% | 56% | August 13, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -1.0% | 40% | October 28, 2025 |
| Any 20-session window (baseline) | -0.3% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LENZ
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 152
- Website
- lenz-tx.com/
Fundamentals
- 1-day range
- $3.43$3.64
- Market cap
- $163.67M
- P/E (trailing)
- —
- P/E (forward)
- -1.23
- EPS (trailing)
- $-4.08
- Dividend yield
- —
- Beta
- 2.20
- Avg. volume
- 775.3K
- Dividend pay date
- March 21, 2024
How LENZ Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
LENZ Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LENZLENZ Therapeutics Inc. Common Stock$3.27▼ 8.40%Market cap $163.67MP/E —$3.35$42.98
- MOLNMolecular Partners AG American Depositary Shares$3.56▼ 2.47%Market cap $163.47MP/E —$2.66$3.96
- ABOSAcumen Pharmaceuticals Inc. Common Stock$1.69▲ 1.20%Market cap $164.68MP/E —$1.5$3.6
- CRBUCaribou Biosciences Inc. Common Stock$0.47▲ 1.08%Market cap $162.66MP/E —$0.4425$3.54
- IPHAInnate Pharma S.A. ADS$1.43▼ 3.38%Market cap $167.42MP/E —$1.03$2.33
- HUMAHumacyte Inc. Common Stock$0.429▼ 2.50%Market cap $157.54MP/E —$0.337$1.9
- TNYATenaya Therapeutics Inc. Common Stock$0.381▼ 6.62%Market cap $157.50MP/E —$0.3601$2.04
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LENZ LENZ Therapeutics Inc. Common Stock | $163.67M | — | $3.27 | ▼ 8.40% | $3.35$42.98 |
| MOLN Molecular Partners AG American Depositary Shares | $163.47M | — | $3.56 | ▼ 2.47% | $2.66$3.96 |
| ABOS Acumen Pharmaceuticals Inc. Common Stock | $164.68M | — | $1.69 | ▲ 1.20% | $1.5$3.6 |
| CRBU Caribou Biosciences Inc. Common Stock | $162.66M | — | $0.47 | ▲ 1.08% | $0.4425$3.54 |
| IPHA Innate Pharma S.A. ADS | $167.42M | — | $1.43 | ▼ 3.38% | $1.03$2.33 |
| HUMA Humacyte Inc. Common Stock | $157.54M | — | $0.429 | ▼ 2.50% | $0.337$1.9 |
| TNYA Tenaya Therapeutics Inc. Common Stock | $157.50M | — | $0.381 | ▼ 6.62% | $0.3601$2.04 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- LENZ Therapeutics: Below Cash For A ReasonSeekingAlpha · 9/25/2026
Insider Activity
Insider Actions →- RA Capital Healthcare Fund LP · June 15, 2026 · Grant22.1K
- James W. McCollum · June 15, 2026 · Grant22.1K
- Guerard Frederic · June 15, 2026 · Grant22.1K
- Scheiner Zachary · June 15, 2026 · Grant22.1K
- Jeffrey P. George · June 15, 2026 · Grant22.1K
- Kimberlee C. Drapkin · June 15, 2026 · Grant22.1K
- Shelley B. Thunen · June 15, 2026 · Grant22.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 33.10M
- Total value held
- $293.01M
- Institutional holders
- 139
- Unknown4.18M
- Unknown3.61M
- Unknown3.60M
- Unknown2.66M
- Unknown1.98M
- Unknown1.51M
- Unknown1.16M
- Unknown1.10M
- Unknown1.04M
- Unknown1.02M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
LENZ Therapeutics faces cash concerns amid low trading levels
A recent analysis highlights LENZ Therapeutics' cash position as a key point of interest for observers. The stock is currently trading near its 52-week low, with an RSI indicating oversold conditions. While analyst targets vary widely, the focus remains on the company's financial liquidity and operational sustainability.
LENZ Therapeutics faces cash concerns amid low trading levels. A recent analysis highlights LENZ Therapeutics' cash position as a key point of interest for observers. The stock is currently trading near its 52-week low, with an RSI indicating oversold conditions. While analyst targets vary widely, the focus remains on the company's financial liquidity and operational sustainability.